Showing 2,221 - 2,240 results of 6,023 for search '(( significant decrease decrease ) OR ( significant potential decrease ))~', query time: 0.54s Refine Results
  1. 2221
  2. 2222

    Supplementary file 1_IGF-1 secreted by mesenchymal stem cells affects the function of lymphatic endothelial progenitor cells: a potential strategy for the treatment of lymphedema.d... by Zekuan Xue (21398444)

    Published 2025
    “…Combined transplantation of MSCs and LEPCs provides an experimental rationale and potential strategy for cell therapy in lymphedema.</p>…”
  3. 2223

    Functional enrichment analysis. by Andrea Salinas (4963834)

    Published 2025
    “…Finally, the extract significantly decreased concanavalin A (ConA)-induced T cell proliferation. …”
  4. 2224

    Data Sheet 1_Comprehensive analysis of metabolism-related genes in sepsis reveals metabolic–immune heterogeneity and highlights GYG1 as a potential therapeutic target.csv by Jie Zheng (31208)

    Published 2025
    “…In vivo, Gyg1 was markedly upregulated in septic mice, and LNP-mediated siRNA knockdown of Gyg1 significantly improved survival in the LPS model. Mechanistically, Gyg1 knockdown significantly reduced glycogen content in myeloid cells, attenuated IL-6 and TNF-α production, alleviated LPS-induced neutrophil, and modestly decreased CD40 expression in monocytes and dendritic cells. …”
  5. 2225

    Data Sheet 1_Therapeutic potential of Cordyceps militaris cultivated with Ginkgo biloba seeds for alleviating western diet-induced type 2 diabetes and diabetic nephropathy.pdf by Shinn-Zong Lin (217003)

    Published 2025
    “…Key biochemical markers, including blood glucose, triglycerides, cholesterol, blood urea nitrogen (BUN), and creatinine, were significantly improved after treatment. Histopathologic analysis revealed restored renal morphology, reduced fibrosis and decreased amyloid deposition. …”
  6. 2226

    Table 1_Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to cha... by Rafaela Ramalho Guerra (22106579)

    Published 2025
    “…</p>Results<p>During early AT, alpha diversity (Shannon index) was significantly lower in sepsis patients compared to non-sepsis patients (2.48 vs. 3.0, p = 0.01), whereas no significant difference was observed after prolonged treatment (2.65 vs. 2.89, p = 0.58). …”
  7. 2227

    Table 1_SRC is a potential target of Arctigenin in treating triple-negative breast cancer: based on machine learning algorithms, molecular modeling and in Vitro test.xlsx by Yuezhou Huang (9998177)

    Published 2025
    “…Western blotting indicated that AG significantly reduced the levels of Bcl-2, caspase-3, and caspase-9, as well as decreased SRC, p-PI3K-p85, p-AKT1, p-MEK1/2, and p-ERK1/2 expression in TNBC cells in a concentration dependent manner.…”
  8. 2228

    Table 2_SRC is a potential target of Arctigenin in treating triple-negative breast cancer: based on machine learning algorithms, molecular modeling and in Vitro test.xlsx by Yuezhou Huang (9998177)

    Published 2025
    “…Western blotting indicated that AG significantly reduced the levels of Bcl-2, caspase-3, and caspase-9, as well as decreased SRC, p-PI3K-p85, p-AKT1, p-MEK1/2, and p-ERK1/2 expression in TNBC cells in a concentration dependent manner.…”
  9. 2229

    Table 3_SRC is a potential target of Arctigenin in treating triple-negative breast cancer: based on machine learning algorithms, molecular modeling and in Vitro test.docx by Yuezhou Huang (9998177)

    Published 2025
    “…Western blotting indicated that AG significantly reduced the levels of Bcl-2, caspase-3, and caspase-9, as well as decreased SRC, p-PI3K-p85, p-AKT1, p-MEK1/2, and p-ERK1/2 expression in TNBC cells in a concentration dependent manner.…”
  10. 2230

    Data Sheet 1_From demyelination to neurodegeneration in multiple sclerosis: reassessing the role of visual evoked potential P100-N145 amplitudes: a missing piece of the puzzle?.zip by Nurhan Kaya Tutar (22327474)

    Published 2025
    “…</p>Results<p>EDSS progression was observed in 17.8% of patients. A longitudinal decrease in P100–N145 amplitude from baseline to follow-up was significantly associated with EDSS progression (OR: 1.511, 95% CI, p < 0.001). …”
  11. 2231

    Table 1_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.xlsx by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  12. 2232

    Image 6_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.jpeg by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  13. 2233

    Image 2_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.jpeg by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  14. 2234

    Image 5_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.jpeg by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  15. 2235

    Image 3_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.jpeg by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  16. 2236

    Image 1_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.jpeg by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  17. 2237

    Table 2_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.docx by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  18. 2238

    Image 4_MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.jpeg by Kai Sun (140584)

    Published 2025
    “…The complex pathogenesis and therapeutic resistance of liver hepatocellular carcinoma (LIHC) present significant clinical challenges. This study investigates MFSD12’s potential involvement in LIHC progression.…”
  19. 2239
  20. 2240

    Table1_Identifying new biomarkers and potential therapeutic targets for breast cancer through the integration of human plasma proteomics: a Mendelian randomization study and coloca... by Jingshuang Song (11340138)

    Published 2024
    “…While some targeted therapies have been developed, there are still significant challenges in early diagnosis and treatment, highlighting the need to identify new biomarkers and therapeutic targets for breast cancer. …”